Personalized cell therapy for Parkinson disease
Aspen Neuroscience is developing the potentially first autologous neuron replacement therapy to treat Parkinson disease. The company’s clinical development encompasses both an autologous neuron replacement therapy in sporadic Parkinson disease (ANPD001) and a gene-edited autologous neuron replacement therapy for familial forms of Parkinson disease (ANPD002).
